BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut. [DOI: 10.1136/gutjnl-2019-319867] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Hernaez R, Thimme R. End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma. Gut 2021:gutjnl-2021-324288. [PMID: 33785552 DOI: 10.1136/gutjnl-2021-324288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yuan J, Peng Y, Hao FB, Wang YQ, Wang CR, Zhong GC. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY) 2021;13:7147-65. [PMID: 33658397 DOI: 10.18632/aging.202573] [Reference Citation Analysis]
3 Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:402-12. [PMID: 34157830 DOI: 10.3350/cmh.2021.0179] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Zhu DM, Xie J, Ye CY, Qian MY, Xue Y. Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy. Can J Gastroenterol Hepatol 2020;2020:8871024. [PMID: 33381476 DOI: 10.1155/2020/8871024] [Reference Citation Analysis]
5 Hu S, Lian PP, Hu Y, Zhu XY, Jiang SW, Ma Q, Li LY, Yang JF, Yang L, Guo HY, Zhou H, Yang CC, Meng XM, Li J, Li HW, Xu T, Zhou H. The Role of IL-35 in the Pathophysiological Processes of Liver Disease. Front Pharmacol 2020;11:569575. [PMID: 33584256 DOI: 10.3389/fphar.2020.569575] [Reference Citation Analysis]
6 Chon HY, Ahn SH, Kim YJ, Yoon JH, Lee JH, Sinn DH, Kim SU. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. Hepatol Int 2021;15:1328-36. [PMID: 34799838 DOI: 10.1007/s12072-021-10262-y] [Reference Citation Analysis]
7 Kim BK, Kim SU. Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology 2021;73:466. [PMID: 32602169 DOI: 10.1002/hep.31439] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]